Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis
Clinical trial NCT01806597 · COMPLETED
Trial details
- NCT number
- NCT01806597
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-06-19
- Primary completion
- 2016-11-02
- Enrollment
- 205
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.